EEG Biomarkers to Predict Response to Sertraline and Placebo Treatment in Major Depressive Disorder
IEEE Transactions on Biomedical Engineering · 2023-03 · 70 (3) · 909-919
DOI: 10.1109/tbme.2022.3204861 ↗Kurz gefasst
Klinische Studie in der Zeitschrift IEEE Transactions on Biomedical Engineering, 2023-03. Verfasst von Thomas Oakley und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Major Depressive Disorder, Sertraline. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: New York Institute of Technology's Institutional Support for Research and Creativity.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Förderung
- New York Institute of Technology's Institutional Support for Research and Creativity
Zitieren
APA
Oakley, T., Coskuner, J., Cadwallader, A., Ravan, M., & Hasey, G. (2023). EEG Biomarkers to Predict Response to Sertraline and Placebo Treatment in Major Depressive Disorder. IEEE Transactions on Biomedical Engineering, 70(3), 909-919. https://doi.org/10.1109/tbme.2022.3204861
Vancouver
Oakley T, Coskuner J, Cadwallader A, Ravan M, Hasey G. EEG Biomarkers to Predict Response to Sertraline and Placebo Treatment in Major Depressive Disorder. IEEE Transactions on Biomedical Engineering. 2023;70(3):909-919. doi:10.1109/tbme.2022.3204861
BibTeX
@article{Oakley2023,
author = {Oakley, Thomas and Coskuner, Jonathan and Cadwallader, Andrew and Ravan, Maryam and Hasey, Gary},
title = {EEG Biomarkers to Predict Response to Sertraline and Placebo Treatment in Major Depressive Disorder},
journal = {IEEE Transactions on Biomedical Engineering},
year = {2023},
volume = {70},
number = {3},
pages = {909--919},
doi = {10.1109/tbme.2022.3204861}
}
EUVIMED